Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandwich Regimen (XELOX/Capecitabine) + RT for pMMR Rectal Cancer
NCT05228431Phase 2Recruiting
- Start
- Mar 2022
- Primary completion
- May 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, capecitabine in rectal cancer. Started Mar 2022; status: recruiting.
02
Drugs
oxaliplatincapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05228431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05228431.